Issue 48, 2023

ZIF-8-based core/shell nanocarriers for relieving multidrug resistance in cancer therapy

Abstract

An effective nanosystem for smart drug delivery requires that the drug be released in a controlled manner at expected locations. Zeolitic imidazolate framework-8 (ZIF-8) with high loading ability and pH-sensitive degradation properties is a suitable candidate for designing such nanoplatforms. However, the Zn2+ ions stemming from the degradation of ZIF-8 could cause toxicity, hindering its further practical application. Herein, to overcome this inherent toxicity, a highly stable, biocompatible, and pH-responsive functionalized ZIF-8 nanocarrier (ZIF-8/lysozyme@hydroxyapatite, ZIF-8/Lys@HAp) is rationally designed via the in situ biomimetic mineralization method. The function of the Lys within the structure is to bond metal ions strongly, thus increasing the rates of nucleation and growth. Importantly, because the overexpression of active efflux transporters is usually responsible for the multidrug resistance (MDR) effect, combining multiple drugs could efficiently avoid MDR compared to a one-drug-loaded platform. Thus, ZIF-8/Lys@HAp is studied as a nanocarrier to achieve efficient codelivery of doxorubicin hydrochloride (anticancer drug) and verapamil hydrochloride (P-glycoprotein inhibitor) to overcome MDR and enhance the therapeutic effect. Our constructed (DOX+VER)-ZIF-8/Lys@HAp represents a promising vehicle in targeted cancer therapy for reversing MDR with enhanced therapeutic efficacy, broadening the applications of ZIF-8 in the biomedical field.

Graphical abstract: ZIF-8-based core/shell nanocarriers for relieving multidrug resistance in cancer therapy

Supplementary files

Article information

Article type
Paper
Submitted
14 Aug 2023
Accepted
14 Nov 2023
First published
17 Nov 2023

New J. Chem., 2023,47, 22495-22507

ZIF-8-based core/shell nanocarriers for relieving multidrug resistance in cancer therapy

J. Gong, X. Li, S. Li, M. Xu and W. Dai, New J. Chem., 2023, 47, 22495 DOI: 10.1039/D3NJ03775D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements